GSK
GSK reported 13 stocks worth $497M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are CRSP (29.0%), VIR (19.2%) and WVE (13.6%). Compared with Q2 2026, the fund opened new positions in WVE, trimmed CRSP and BNTX and sold out of WVE.
Latest filing: what GSK did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() CRSP Crispr Therapeutics | $144M | 29.0% | 2.6M | −612K (−19%) | 4 of 4 | |
| 2 | ![]() VIR Vir Biotechnology Inc | $95.6M | 19.2% | 8.6M | No change | 4 of 4 | |
| 3 | ![]() WVE Wave Life Sciences Inc. | $67.5M | 13.6% | 18.2M | New position | 1 of 4 | |
| 4 | ![]() BNTX Biontech SE | $65.7M | 13.2% | 669K | −221K (−25%) | 4 of 4 | |
| 5 | ![]() IDYA Ideaya Biosciences Inc | $51.2M | 10.3% | 1.3M | No change | 4 of 4 | |
| 6 | ![]() CYTK Cytokinetics Inc | $22.4M | 4.5% | 340K | No change | 4 of 4 | |
| 7 | ![]() LYEL Lyell Immunopharma Inc | $14.8M | 3.0% | 1.5M | No change | 4 of 4 | |
| 8 | ![]() SPRO Spero Therapeutics Inc | $11.1M | 2.2% | 9.2M | No change | 4 of 4 | |
| 9 | ![]() NKTX Nkarta Inc | $8.3M | 1.7% | 3.2M | No change | 4 of 4 | |
| 10 | ![]() FULC Fulcrum Therapeutics Inc | $6.6M | 1.3% | 1.8M | No change | 4 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() WVE Wave Life Sciences Ltd | $106M | 18.2M |
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 5, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →GSK 13F FAQ
What does GSK own?
GSK reported 13 stocks worth $497M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are CRSP (29.0%), VIR (19.2%) and WVE (13.6%). The table above lists every position in the filing (the top 10 without an account).
What did GSK buy and sell in Q3 2026?
Compared with Q2 2026: 1 new positions, 0 added to, 2 trimmed and 1 sold out. New positions include WVE. It sold all of WVE.
When will GSK file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is GSK's portfolio worth?
The Q3 2026 filing reports $497M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.









